SIM
DAWN

Sandia Investment Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Sandia Investment Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,980
Closed -$87.3K – 143
2023
Q4 		$87.3K Sell
5,980
-4,020
-40% -$48.7K 0.06% 115
2023
Q3 		$123K Hold
10,000
– – 0.03% 134
2023
Q2 		$119K Buy
+10,000
New +$131K 0.03% 147

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sandia Investment Management's DAWN Position: Q1 2024 in Review

Sandia Investment Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2024, closing a stake of 5,980 shares — an estimated $87.3K sold.

Sandia Investment Management first reported a position in DAWN in Q2 2023 and held it in 3 quarters. The position peaked at $123K in Q3 2023. 149 funds tracked by Wall St. Rank hold DAWN as of Q1 2024.

  • Sandia Investment Management reported no remaining Day One Biopharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Sandia Investment Management sold 5,980 Day One Biopharmaceuticals shares in Q1 2024, an estimated $87.3K.
  • Sandia Investment Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Sandia Investment Management's Day One Biopharmaceuticals position peaked at $123K in Q3 2023.
  • 149 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2024.

Based on Sandia Investment Management's 13F filing for Q1 2024, filed 15 May 2024.